370 related articles for article (PubMed ID: 30108109)
1. How ibrutinib, a B-cell malignancy drug, became an FDA-approved second-line therapy for steroid-resistant chronic GVHD.
Jaglowski SM; Blazar BR
Blood Adv; 2018 Aug; 2(15):2012-2019. PubMed ID: 30108109
[TBL] [Abstract][Full Text] [Related]
2. Ibrutinib for the treatment of patients with chronic graft-versus-host disease after failure of one or more lines of systemic therapy.
Rahmat LT; Logan AC
Drugs Today (Barc); 2018 May; 54(5):305-313. PubMed ID: 29911695
[TBL] [Abstract][Full Text] [Related]
3. Inhibition of BTK and ITK with Ibrutinib Is Effective in the Prevention of Chronic Graft-versus-Host Disease in Mice.
Schutt SD; Fu J; Nguyen H; Bastian D; Heinrichs J; Wu Y; Liu C; McDonald DG; Pidala J; Yu XZ
PLoS One; 2015; 10(9):e0137641. PubMed ID: 26348529
[TBL] [Abstract][Full Text] [Related]
4. Ibrutinib for chronic graft-versus-host disease after failure of prior therapy.
Miklos D; Cutler CS; Arora M; Waller EK; Jagasia M; Pusic I; Flowers ME; Logan AC; Nakamura R; Blazar BR; Li Y; Chang S; Lal I; Dubovsky J; James DF; Styles L; Jaglowski S
Blood; 2017 Nov; 130(21):2243-2250. PubMed ID: 28924018
[TBL] [Abstract][Full Text] [Related]
5. An Open-Label, Single-Arm, Multicenter Study of Ibrutinib in Japanese Patients With Steroid-dependent/Refractory Chronic Graft-Versus-Host Disease.
Doki N; Toyosaki M; Shiratori S; Osumi T; Okada M; Kawakita T; Sawa M; Ishikawa T; Ueda Y; Yoshinari N; Nakahara S
Transplant Cell Ther; 2021 Oct; 27(10):867.e1-867.e9. PubMed ID: 34102349
[TBL] [Abstract][Full Text] [Related]
6. Ibrutinib treatment ameliorates murine chronic graft-versus-host disease.
Dubovsky JA; Flynn R; Du J; Harrington BK; Zhong Y; Kaffenberger B; Yang C; Towns WH; Lehman A; Johnson AJ; Muthusamy N; Devine SM; Jaglowski S; Serody JS; Murphy WJ; Munn DH; Luznik L; Hill GR; Wong HK; MacDonald KK; Maillard I; Koreth J; Elias L; Cutler C; Soiffer RJ; Antin JH; Ritz J; Panoskaltsis-Mortari A; Byrd JC; Blazar BR
J Clin Invest; 2014 Nov; 124(11):4867-76. PubMed ID: 25271622
[TBL] [Abstract][Full Text] [Related]
7. FDA review summary of patient-reported outcome results for ibrutinib in the treatment of chronic graft versus host disease.
King-Kallimanis BL; Wroblewski T; Kwitkowski V; De Claro RA; Gwise T; Bhatnagar V; Farrell AT; Kluetz PG
Qual Life Res; 2020 Jul; 29(7):1903-1911. PubMed ID: 32100182
[TBL] [Abstract][Full Text] [Related]
8. Ibrutinib in Steroid-Refractory Chronic Graft-versus-Host Disease, a Single-Center Experience.
Chin KK; Kim HT; Inyang EA; Ho V; Koreth J; Romee R; Gooptu M; Shapiro R; Antin J; Soiffer R; Jaglowski S; Pidala J; Cutler C
Transplant Cell Ther; 2021 Dec; 27(12):990.e1-990.e7. PubMed ID: 34481113
[TBL] [Abstract][Full Text] [Related]
9. Ruxolitinib in the management of steroid-resistant/-dependent acute and chronic graft-versus-host disease: results of routine practice in an academic centre.
Leung GMK; Sim JPY; Hwang YY; Chan TSY; Lie AKW; Tse E; Kwong YL
Ann Hematol; 2022 Jan; 101(1):155-163. PubMed ID: 34767056
[TBL] [Abstract][Full Text] [Related]
10. Ibrutinib for Chronic Graft-versus-Host Disease After Failure of Prior Therapy: 1-Year Update of a Phase 1b/2 Study.
Waller EK; Miklos D; Cutler C; Arora M; Jagasia MH; Pusic I; Flowers MED; Logan AC; Nakamura R; Chang S; Clow F; Lal ID; Styles L; Jaglowski S
Biol Blood Marrow Transplant; 2019 Oct; 25(10):2002-2007. PubMed ID: 31260802
[TBL] [Abstract][Full Text] [Related]
11. Three US Food and Drug Administration-approved therapies for chronic GVHD.
Zeiser R; Lee SJ
Blood; 2022 Mar; 139(11):1642-1645. PubMed ID: 35081254
[TBL] [Abstract][Full Text] [Related]
12. Recent FDA Approvals in the Treatment of Graft-Versus-Host Disease.
Martini DJ; Chen YB; DeFilipp Z
Oncologist; 2022 Aug; 27(8):685-693. PubMed ID: 35443042
[TBL] [Abstract][Full Text] [Related]
13. Concomitant Ruxolitinib and Ibrutinib for Graft-Versus-Host Disease (GVHD): The First Reported Use in Pediatric Patients.
Gagliardi TA; Milner J; Cairo MS; Steinberg A
Cureus; 2022 Sep; 14(9):e29195. PubMed ID: 36258935
[TBL] [Abstract][Full Text] [Related]
14. Ibrutinib Treatment of Pediatric Chronic Graft-versus-Host Disease: Primary Results from the Phase 1/2 iMAGINE Study.
Carpenter PA; Kang HJ; Yoo KH; Zecca M; Cho B; Lucchini G; Nemecek ER; Schultz KR; Stepensky P; Chaudhury S; Oshrine B; Khaw SL; Harris AC; Verna M; Zubarovskaya L; Lee Y; Wahlstrom J; Styles L; Shaw PJ; Dalle JH
Transplant Cell Ther; 2022 Nov; 28(11):771.e1-771.e10. PubMed ID: 36044977
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and Safety of Ibrutinib for Chronic Graft-Versus-Host Disease: A Systematic Review.
Santosa D; Rizky D; Tandarto K; Kartiyani I; Yunarvika V; Ardini DNE; Setiawan B; Pangarsa EA; Suharti C
Asian Pac J Cancer Prev; 2023 Dec; 24(12):4025-4033. PubMed ID: 38156834
[TBL] [Abstract][Full Text] [Related]
16. Evolving Therapeutic Options for Chronic Graft-versus-Host Disease.
Gonzalez RM; Pidala J
Pharmacotherapy; 2020 Aug; 40(8):756-772. PubMed ID: 32441379
[TBL] [Abstract][Full Text] [Related]
17. Clinical utility of rituximab in chronic graft-versus-host disease.
Bates JS; Engemann AM; Hammond JM
Ann Pharmacother; 2009 Feb; 43(2):316-21. PubMed ID: 19193571
[TBL] [Abstract][Full Text] [Related]
18. Ruxolitinib for chronic steroid-refractory graft versus host disease: a single center experience.
Xue E; Lorentino F; Pavesi F; Assanelli A; Peccatori J; Bernardi M; Corti C; Ciceri F; Lupo Stanghellini MT
Leuk Res; 2021 Oct; 109():106642. PubMed ID: 34157510
[TBL] [Abstract][Full Text] [Related]
19. Healthcare resource utilization and costs among patients with steroid-resistant chronic graft-versus-host disease in the United States: a retrospective claims database analysis.
Yu J; Lal LS; Anderson A; DuCharme M; Parasuraman S; Weisdorf D
Curr Med Res Opin; 2021 May; 37(5):755-759. PubMed ID: 33615925
[TBL] [Abstract][Full Text] [Related]
20. Novel Approaches to the Treatment of Chronic Graft-Versus-Host Disease.
Zeiser R
J Clin Oncol; 2023 Apr; 41(10):1820-1824. PubMed ID: 36800551
[No Abstract] [Full Text] [Related]
[Next] [New Search]
